Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Novo Nordisk faces challenges but its pipeline remains strong. Find out why NVO stock could deliver high double-digit returns ...

Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The decliners were Novo Nordisk (NYSE ... clinical trials. So this is basically ...

To do so, Novo Nordisk’s CFO, Karsten Munk Knudsen, says the company is now looking at the next generation of weight loss drugs ... who are unsure as to why the remaining patients reduced ...

Danish weight-loss drug maker Novo Nordisk (NVO) is jumping 5% after the ... a weight loss pill in the U.S. before its key rival does so. The company markets the popular weight-loss drug, Wegovy.

Danish weight-loss drug maker Novo Nordisk (NVO) is jumping 5% after the company reported ... be able to introduce a weight loss pill in the U.S. before its key rival does so. The company markets the ...

It said not doing so would be more expensive in the long term. Vials of Wegovy at a Novo Nordisk production line in Hillerod, Denmark. The company argues government subsidies for its weight-loss ...

So this is basically ... the company's compounded weight-loss drug business; such are the perils of legal loopholes. By the same token, I wouldn't sell either Novo Nordisk or Viking simply because ...